by Raynovich Rod | Feb 27, 2014 | 2025 Rayno Biopharmaceuticals Portfolio, Clinical Diagnostics and Tools
Rayno Life Science Movers -Diagnostics Review Next Week Despite some choppiness in biotech trading this week many of our stocks did well. I won’t go into some of the unusual volatility in other small and mid-caps lately but that is part of the reason for my...
by Raynovich Rod | Feb 25, 2014 | 2025 Rayno Biopharmaceuticals Portfolio
Biotech May Be A Bubble-But What to Do? The blogosphere is trying to temper bullish sentiment with a lot of “bubble “talk even though the cable channels are still pumping biotech. If you have been around biotech for 25 years especially during the last...
by Raynovich Rod | Feb 18, 2014 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Update 2/21: Life Science stocks have blown through new highs this AM Large and mid-cap biopharma: ALKS BIIB,PCYC,REGN SGEN etc ETFs: IBB ($270) and XBI ($165) at new highs Two Rayno Dx laggard stocks on the move: RGDX and VRML. ———- Rayno Life...
by Raynovich Rod | Feb 11, 2014 | 2025 Rayno Biopharmaceuticals Portfolio
Large Cap Biotechs Hover Near January 2014 Highs IBB At $254 on 2/11/14 The biotechnology sector has come roaring back after a 5-7% correction in February. Only one stock is at a new high Alexion (ALXN $171) . Many speculative mid and small caps are doing slightly...
by Raynovich Rod | Feb 9, 2014 | 2025 Rayno Biopharmaceuticals Portfolio
Life Science Stocks Surge Ahead From February Lows NASDAQ Up 1.67%, IBB Up 4%, FBIOX up 4.72%, XBI up 5.64%, XLV up 1.7% The soaring biotech sector would not let a losing week go by and took off early Friday erasing most losses for the week 2/3 to 2/7. Institutions...
by Raynovich Rod | Feb 3, 2014 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
But Momentum Is Easing As Investors Cash Out-IBB Is 5.5% Off Jan 22 Highs Caution Rules With Selling Pressure-Raise Cash to 15% January 2014 was up 12% which may be the best month ever in biotechnology at peak prices on January 22. But with the sector up over 62%...
by Raynovich Rod | Jan 30, 2014 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
Update 12:40p NASDAQ Up 2% Cardiovascular Sciences (CSII $33.90) Up 15 %-Beats on Revenues and EPS. Q2 Revenues up 28% to $32.3M. Net Loss was $8.7M compared to $5.8M in 2013 fiscal Q2. Thermo Fisher (TMO $114) up 2.4% on 10% 2013 EPS gain. Q4 revenues up 6% to...
by Raynovich Rod | Jan 28, 2014 | 2025 Rayno Biopharmaceuticals Portfolio
Plenty Of FirePower Left In Biotech-IBB Up 2.2% At $244 Biotechnology stocks have been quite volatile and not immune to downdrafts but today they made an impressive recovery. Nonetheless I would be selective and not trade the small cap high fliers unless you did your...
by Raynovich Rod | Jan 20, 2014 | 2025 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
2014 J.P.Morgan Healthcare Conference Update #4-Rayno Biopharmaceutical Picks Biotechnology started off with a roar and major indices were up 10% or more. Much of it can be attributed to the excitement and anticipation of the JPMorgan Conference with 10,000 attendees...
by Raynovich Rod | Jan 16, 2014 | 2024 Rayno Tools and Diagnostics Portfolio, 2025 Rayno Biopharmaceuticals Portfolio
Biotech Rally Continues With IBB ($245) At New Highs-Up 10 Pts. From Monday’s Bottom Several Rayno Life Science picks were up after presentations at the 2014 J.P.Morgan Healthcare Conference. All of our portfolio picks are strong holds unless otherwise noted....
